ADMA Biologics CEO Adam Grossman sells $1.76M in shares
What it means
- What to watch: This one turns on a concrete figure ($1); set it against the recent trend before reading it as a turning point.
- How the stock is trading: $ADMA +26.05% in the latest session.
- Timing: It landed while New York slept, so the session change beside it belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
$ADMA last changed hands at $13.21, +26.05% on the session, 35% below its 52-week high of $20.46 and 83% above its low of $7.21 — around the middle of the range. Over the year it has ranged 184% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ADMA page.
How much coverage it is getting
This is the only story Wook has logged on $ADMA in the last 30 days — a quiet name that just got a headline. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
What to watch next
The $ADMA page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $ADMA sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ADMA. It carried $1.76 million, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.